Prof. at Div. of Infectious Diseases Therapeutics, Kobe Univ. Grad. School of Medicine. コメントは個人の見解。特に断りなく、想定読者は変幻させているので読んで「分からん」と思ったら自分宛てじゃないとスルーしてください
U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients